Bivalent KDP Peptide to Enhance Neurite Growth for Traumatic Brain Injury
Defence Life Science Journal · 2016
DOI: 10.14429/dlsj.1.10062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Defence Life Science Journal, 2016. Verfasst von Raunak Varshney und 1 weiteren Autor:innen.
Abstract (Originalsprache)
A silent epidemic of modern world and largely neglected field in drug development is traumatic brain injury. There is no treatment available for the patients suffering from brain trauma. Peptide is a naturally occurring biological alternative that could represent a new generation of future medications. In this study, we have designed and modified the C-terminal amino acids of KDI peptide responsible for neurite growth. The inclusion of a Cys (C), Gly (G), Cys and Pro (P) amino acids in the sequence leads to the possibility of better binding with the target receptor 3T1M as compared to the known KDI sequence for neurite growth. Studies on human SH-SY5Y cells for neurite outgrowth demonstrates that the CGCKDP could plausibly be useful in neuroregeneration in neurodegenerative disorders by neurite growth formation.
Zitieren
APA
Varshney, R., & Mishra, A. K. (2016). Bivalent KDP Peptide to Enhance Neurite Growth for Traumatic Brain Injury. Defence Life Science Journal. https://doi.org/10.14429/dlsj.1.10062
Vancouver
Varshney R, Mishra AK. Bivalent KDP Peptide to Enhance Neurite Growth for Traumatic Brain Injury. Defence Life Science Journal. 2016. doi:10.14429/dlsj.1.10062
BibTeX
@article{Varshney2016,
author = {Varshney, Raunak and Mishra, Anil K.},
title = {Bivalent KDP Peptide to Enhance Neurite Growth for Traumatic Brain Injury},
journal = {Defence Life Science Journal},
year = {2016},
doi = {10.14429/dlsj.1.10062}
}
EUVIMED